机构:[1]Department of Hematology, Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine[2]Department of Hematology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital[3]Department of Hematology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine[4]Department of Blood Transfusion, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
Remodeling of adipocyte morphology and function plays a critical role in prostate cancer development. We previously reported that leukemia cells secrete growth differentiation factor 15 (GDF15), which remodels the residual bone marrow (BM) adipocytes into small adipocytes and is associated with a poor prognosis in patients with acute myeloid leukemia. However, little is known about how GDF15 drives BM adipocyte remodeling. In this study, we examined the role of the transient receptor potential vanilloid (TRPV) channels in the remodeling of BM adipocytes exposed to GDF15. We found that TRPV4 negatively regulated GDF15-induced remodeling of BM adipocytes. Furthermore, transforming growth factor-beta type II receptor was identified as the main receptor for GDF15 on BM adipocytes. PI3K inhibitor treatment reduced GDF15-induced pAKT, identifying PI3K/AKT as the downstream stress response pathway. Subsequently, GDF15 reduced the expression of the transcription factor Forkhead box C1 (FOXC1) in BM adipocytes subjected to RNA-sequencing screening and western blot analysis. Moreover, it was also confirmed that FOXC1 combined with the TRPV4 promoter by chromatin immunoprecipitation with quantitative polymerase chain reaction experiments, which suggests that FOXC1 mediates GDF15 regulation of TRPV4. In addition, an acute myeloid leukemia mouse model exhibited smaller BM adipocytes, whereas the TRPV4 activator 4a-phorbol 12,13-didecanoate partly rescued this process and increased survival. In conclusion, TRPV4 plays a critical role in BM adipocyte remodeling induced by leukemia cells, suggesting that targeting TRPV4 may constitute a novel strategy for acute myeloid leukemia therapy.
基金:
National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81870132]; Science and Technology Commission of Shanghai MunicipalityScience & Technology Commission of Shanghai Municipality (STCSM) [18DZ2293500]; Shanghai Sailing Program [18YF1419100]